
Nymox Pharmaceutical Corporation NYMX
Annual report 2024
added 03-07-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
- |
Market Cap[1] |
$ 18.4 M |
EBITDA (LTM) |
$ -13.8 M |
P/E (LTM) |
- |
P/S (LTM) |
195.6 |
EPS (LTM) |
-0.17 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
$ 0.79 | -1.15 % | $ 4.31 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 3.49 | 0.58 % | $ 1.04 B | Nasdaq Global Select Market | ||
|
Frequency Therapeutics
FREQ
|
- | - | $ 528 M | Nasdaq Global Select Market | ||
|
argenx SE
ARGX
|
$ 700.45 | -1.19 % | $ 25 B | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.6 | 1.41 % | $ 8.66 B | Nasdaq Capital Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Grifols, S.A.
GRFS
|
$ 7.81 | -2.01 % | $ 6.83 B | Nasdaq Global Select Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 225.98 | -1.32 % | $ 5 B | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
ADC Therapeutics SA
ADCT
|
$ 4.13 | -5.06 % | $ 105 M | NYSE | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
BioCardia
BCDA
|
$ 1.26 | -0.79 % | $ 26.7 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Anika Therapeutics
ANIK
|
$ 14.2 | -0.7 % | $ 208 M | Nasdaq Global Select Market,SPB | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 91.19 | 1.21 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.44 | -1.37 % | $ 367 M | Nasdaq Global Select Market | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 6.68 | -4.57 % | $ 183 M | Nasdaq Global Market,SPB | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | ||
|
Burford Capital Limited
BUR
|
$ 7.92 | 1.67 % | $ 1.31 B | NYSE | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Aytu BioScience
AYTU
|
$ 2.54 | -5.22 % | $ 16 M | Nasdaq Capital Market | ||
|
Certara
CERT
|
$ 6.67 | 1.6 % | $ 1.07 B | Nasdaq Global Select Market | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 3.6 | -4.0 % | $ 7.83 B | NYSE American | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.